Carvacrol

Pharmacology & Research

Carvacrol is a monoterpenoid phenol — the dominant aromatic active of oregano essential oil, also present in savory and thyme, and a positional isomer of thymol. It gives these herbs their warm, pungent character and is one of the most-studied natural antimicrobials. The framing that matters most: almost all human evidence is for the essential oil or multi-herb blends, not for isolated carvacrol — the molecule’s own strong data are in the laboratory. Its marquee action is broad antimicrobial and anti-biofilm activity, mechanistically pinned to disruption of the microbial membrane ^{1Reference 1Ultee A et al. · 1999Mechanisms of action of carvacrol on the food-borne pathogen Bacillus cereusView study →}, and its best-defined molecular pharmacology is as an agonist of the TRPV3 and TRPA1 ion channels ^{3,4Reference 3Xu H et al. · 2006Oregano, thyme and clove-derived flavors and skin sensitizers activate specific TRP channelsView study →Reference 42020Non-electrophilic TRPA1 agonists menthol, carvacrol and clotrimazole open epithelial tight junctions via TRPA1 activationView study →} — which also explains why concentrated carvacrol is a sensory irritant. Its pharmacokinetics (rapid conjugation, low free-plasma levels) mean the impressive dish-level potency is best understood at mucosal and surface sites, not as a systemic drug ^{7Reference 72012Identification of UDP-glucuronosyltransferase isoforms involved in the hepatic and intestinal glucuronidation of carvacrolView study →}.

1. Antimicrobial / anti-biofilm

This is carvacrol’s strongest and best-isolated evidence. It has broad activity against Gram-positive and Gram-negative bacteria and Candida, including mature biofilms that resist fluconazole, plus quorum-sensing interference and synergy with thymol ^{12,13,14,15,16Reference 122018The natural plant compound carvacrol as an antimicrobial and anti-biofilm agent: mechanisms, synergies and bio-inspired anti-infective materialsView study →Reference 132006Antimicrobial activity of carvacrol related to its chemical structureView study →Reference 142006Structural requirements for the antimicrobial activity of carvacrolView study →Reference 152020Synergistic antimicrobial combination of carvacrol and thymol impairs single and mixed-species biofilms of Candida albicans and Staphylococcus epidermidisView study →Reference 162021In-vitro activities of carvacrol, cinnamaldehyde and thymol against Candida biofilmsView study →}. The mechanism is well worked out: carvacrol permeabilises the cytoplasmic membrane and acts as a proton carrier, collapsing the proton-motive force and depleting ATP ^{1Reference 1Ultee A et al. · 1999Mechanisms of action of carvacrol on the food-borne pathogen Bacillus cereusView study →}, and structure-activity work shows the free phenolic hydroxyl is essential for this action ^{2Reference 2Ultee A et al. · 2002The phenolic hydroxyl group of carvacrol is essential for action against the food-borne pathogen Bacillus cereusView study →}.

Gap: almost entirely in-vitro or food-matrix; there is no isolated-carvacrol human infection trial, and the MICs achieved in a dish are not necessarily reached in plasma (see Pharmacokinetics) ^{1,7Reference 1Ultee A et al. · 1999Mechanisms of action of carvacrol on the food-borne pathogen Bacillus cereusView study →Reference 72012Identification of UDP-glucuronosyltransferase isoforms involved in the hepatic and intestinal glucuronidation of carvacrolView study →}.

2. TRP-channel pharmacology

The best-characterised molecular action of pure carvacrol: it is a strong agonist/sensitiser of the warmth-sensing channel TRPV3 (the basis of its warm, pungent oral sensation and skin-sensitiser status) ^{3Reference 3Xu H et al. · 2006Oregano, thyme and clove-derived flavors and skin sensitizers activate specific TRP channelsView study →} and an agonist of the irritant channel TRPA1, which opens epithelial tight junctions and, in one rodent model, mediated protection against intestinal mucositis ^{4,5Reference 42020Non-electrophilic TRPA1 agonists menthol, carvacrol and clotrimazole open epithelial tight junctions via TRPA1 activationView study →Reference 52016Carvacrol reduces irinotecan-induced intestinal mucositis through inhibition of inflammation and oxidative damage via TRPA1 receptor activationView study →}. It also inhibits TRPM7 ^{6Reference 6Parnas M et al. · 2009Carvacrol is a novel inhibitor of Drosophila TRPL and mammalian TRPM7 channelsView study →}.

Gap: this is sensory/irritant biology and target identification, not a validated therapy — and the tight-junction effect is double-edged, acting as both a permeation enhancer and an irritant ^{4Reference 42020Non-electrophilic TRPA1 agonists menthol, carvacrol and clotrimazole open epithelial tight junctions via TRPA1 activationView study →}.

3. Anti-inflammatory

In rodent models and LPS-stimulated macrophages, carvacrol reduces pro-inflammatory mediators (IL-1β, nitric oxide, PGE2) and suppresses NF-κB signalling ^{18,11Reference 182016Modulatory effects of thymol and carvacrol on inflammatory transcription factors in lipopolysaccharide-treated macrophagesView study →Reference 11Mączka W et al. · 2023Carvacrol — a natural phenolic compound with antimicrobial propertiesView study →}, with evidence that induction of the anti-inflammatory cytokine IL-10 is a key effector ^{17Reference 172013Anti-inflammatory effects of carvacrol: evidence for a key role of interleukin-10View study →}.

Gap: animal and cell only, often at high doses, with no isolated-carvacrol human anti-inflammatory trial ^{17,18Reference 172013Anti-inflammatory effects of carvacrol: evidence for a key role of interleukin-10View study →Reference 182016Modulatory effects of thymol and carvacrol on inflammatory transcription factors in lipopolysaccharide-treated macrophagesView study →}.

4. Antioxidant

Carvacrol is a direct phenolic radical scavenger and engages Nrf2/HO-1 antioxidant signalling in organ-injury models ^{11,12Reference 11Mączka W et al. · 2023Carvacrol — a natural phenolic compound with antimicrobial propertiesView study →Reference 122018The natural plant compound carvacrol as an antimicrobial and anti-biofilm agent: mechanisms, synergies and bio-inspired anti-infective materialsView study →}.

Gap: mechanistically plausible but largely descriptive; the Nrf2 data are model-specific and there is no verified standalone human antioxidant trial ^{11Reference 11Mączka W et al. · 2023Carvacrol — a natural phenolic compound with antimicrobial propertiesView study →}.

5. Antiparasitic

Carvacrol is active against Leishmania infantum and L. amazonensis promastigotes and amastigotes in vitro and in a murine model, with synergy in combination with ascaridole and caryophyllene oxide ^{8,9Reference 82015Combinations of ascaridole, carvacrol and caryophyllene oxide against LeishmaniaView study →Reference 92019In-vitro and in-vivo effectiveness of carvacrol, thymol and linalool against Leishmania infantumView study →} — overlapping the antiprotozoal narrative around oregano/epazote oils.

Gap: parasite-model only, no human data, and host-cell selectivity at the active concentrations is a concern ^{8,9Reference 82015Combinations of ascaridole, carvacrol and caryophyllene oxide against LeishmaniaView study →Reference 92019In-vitro and in-vivo effectiveness of carvacrol, thymol and linalool against Leishmania infantumView study →}.

6. Anticancer

Carvacrol is pro-apoptotic across many cancer cell lines (caspase activation, altered Bax/Bcl-2, cell-cycle arrest, ROS), as summarised in a 2021 systematic review ^{10Reference 102021Systematic reviewAntitumor effects of carvacrol and thymol: a systematic reviewView study →}.

Gap: that review counted 77 studies of which 69 were in vitro and only 10 in vivo — there is zero human oncology data, and active concentrations are high ^{10Reference 102021Systematic reviewAntitumor effects of carvacrol and thymol: a systematic reviewView study →}.

Mechanisms

Target / pathway	Effect	Relevant to
Cytoplasmic-membrane permeabilisation; proton-motive-force collapse	K⁺/H⁺ leak, ATP depletion → bactericidal	antimicrobial (primary)
Free phenolic hydroxyl (structure-activity)	the –OH is required for antimicrobial potency	antimicrobial SAR
TRPV3 agonist / sensitiser	Ca²⁺ influx; warm-pungent sensation, skin sensitisation	sensory effects, topical irritation
TRPA1 agonist	channel activation → tight-junction opening	sensory/irritant, gut epithelium
TRPM7 inhibition	channel block	ion-channel pharmacology (mechanistic)
NF-κB suppression; IL-10 induction	↓ iNOS/COX-2, ↓ NO/PGE2	anti-inflammatory
Nrf2 / antioxidant response (model-dependent)	↑ antioxidant defences	antioxidant, organ protection

Pharmacokinetics

Carvacrol behaves like a typical volatile essential-oil phenol — rapidly absorbed, extensively conjugated, rapidly cleared, with low free systemic exposure. Glucuronidation is characterised in human liver and intestinal microsomes, with UGT1A9 the major isoform ^{7Reference 72012Identification of UDP-glucuronosyltransferase isoforms involved in the hepatic and intestinal glucuronidation of carvacrolView study →}, and CYP-mediated phase-I metabolism of carvacrol and thymol is also demonstrated in human liver microsomes ^{20Reference 202012Identification of CYP isoforms involved in the metabolism of thymol and carvacrol in human liver microsomesView study →}. Free carvacrol in plasma is very low; the circulating pool is dominated by conjugated metabolites ^{21Reference 212018Pharmacokinetics and antimicrobial activity of a new carvacrol-based product against Campylobacter jejuniView study →}. Its high volatility adds formulation and GI losses. The practical implication: the impressive in-vitro MICs and micromolar cell-culture effects may not be reached in blood after oral dosing, so activity is most plausible at mucosal, luminal and topical surfaces (gut, mouth, skin) where local concentrations are high — not as a systemic drug.

Clinical trials

There is no completed RCT of isolated carvacrol. The human evidence is for oregano/thyme essential-oil or multi-herb preparations: an open-label comparative study found a herbal antimicrobial protocol (blends that include oregano oil) statistically non-inferior to rifaximin for normalising SIBO breath tests ^{22Reference 22Chedid V et al. · 2014Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowthView study →} — a blend, open-label, hypothesis-generating, not confirmatory. Everything human-relevant traces to the oil, not the molecule.

Last checked: July 2026.

Toxicity & Safety

Carvacrol is consumed in small amounts as a flavouring and is classified safe as a flavouring (JECFA/FDA/EU) — a food-additive clearance at low dietary levels, not an endorsement of supplement doses ^{11,19Reference 11Mączka W et al. · 2023Carvacrol — a natural phenolic compound with antimicrobial propertiesView study →Reference 19De Vincenzi M et al. · 2004Constituents of aromatic plants: carvacrolView study →}. In concentrated form it is a skin and mucous-membrane irritant and a documented skin sensitiser, mechanistically consistent with its TRPV3/TRPA1 agonism — undiluted oregano oil should be handled diluted ^{3,4Reference 3Xu H et al. · 2006Oregano, thyme and clove-derived flavors and skin sensitizers activate specific TRP channelsView study →Reference 42020Non-electrophilic TRPA1 agonists menthol, carvacrol and clotrimazole open epithelial tight junctions via TRPA1 activationView study →}. Toxicity is dose-dependent: low doses are well tolerated in animals (adverse effects generally absent below ~50 mg/kg body weight), while high concentrations show cytotoxicity and genotoxicity in vitro and high oral doses can produce GI and hepatic effects ^{11Reference 11Mączka W et al. · 2023Carvacrol — a natural phenolic compound with antimicrobial propertiesView study →}. A 90-day oral rat study of carvacrol-dominant Origanum vulgare essential oil found no treatment-related adverse effects at the tested levels — reassuring for the oil, though not a pure-carvacrol NOAEL ^{23Reference 232017AnimalA subchronic 90-day oral toxicity study of Origanum vulgare essential oil in ratsView study →}. Drug interactions are theoretical and low-confidence: as a UGT1A9/CYP substrate it could in principle interact with co-metabolised drugs, and its TRPA1/permeation effects might enhance absorption of co-administered agents — no human interaction data exist.

Dosage

There is no established or recommended human dose for isolated carvacrol — the figures here are research and food-additive references, not a recommendation. Its only regulatory clearance is as a low-level flavouring, at trace amounts well below toxicological thresholds ^{19Reference 19De Vincenzi M et al. · 2004Constituents of aromatic plants: carvacrolView study →}. Preclinical rodent efficacy studies commonly use ~10–80 mg/kg orally, with adverse effects generally absent below ~50 mg/kg ^{11Reference 11Mączka W et al. · 2023Carvacrol — a natural phenolic compound with antimicrobial propertiesView study →} — animal figures that do not extrapolate to people. The human clinical context uses standardised oregano-oil blend capsules of product-defined, variable carvacrol content ^{22Reference 22Chedid V et al. · 2014Herbal therapy is equivalent to rifaximin for the treatment of small intestinal bacterial overgrowthView study →}, not weighed carvacrol.

References